Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting
HOUSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting, taking place from March 29 – April 3, 2019 in Atlanta, GA.
Details for the poster presentation are as follows:
Date: Wednesday, April 3, 2019 Presentation Time: 8:00 am – 12:00 pm Eastern Time Location: Georgia World Congress Center, Exhibit Hall B Session: Gene- and Vector-Based Therapy, Poster Section 12 Abstract: 4786 Title: “BP1003, A Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor”
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that hasyielded a pipeline of RNAi nanoparticle drugs that can be administered with a simpleintravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company’s website at http://www.biopathholdings.com.
Will O’ConnorStern Investor Relations, Inc.212-362-1200 firstname.lastname@example.org
Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369